Genome-wide association meta-analysis identifies five modifier loci of lung disease severity in cystic fibrosis
2015; Nature Portfolio; Volume: 6; Issue: 1 Linguagem: Inglês
10.1038/ncomms9382
ISSN2041-1723
AutoresHarriet Corvol, Scott M. Blackman, Pierre‐Yves Boëlle, Paul J. Gallins, Rhonda G. Pace, Jaclyn R. Stonebraker, Frank J. Accurso, Annick Clément, Joseph M. Collaco, Hong Dang, Anthony T. Dang, Arianna Franca, Jiafen Gong, Loïc Guillot, Katherine Keenan, Weili Li, Lin Fan, Michael V. Patrone, Karen S. Raraigh, Lei Sun, Yi‐Hui Zhou, Emily S. Wan, Marci K. Sontag, Hara Levy, Peter R. Durie, Johanna M. Rommens, Mitchell L. Drumm, Fred A. Wright, Lisa J. Strug, Garry R. Cutting, Michael R. Knowles,
Tópico(s)Neonatal Respiratory Health Research
ResumoThe identification of small molecules that target specific CFTR variants has ushered in a new era of treatment for cystic fibrosis (CF), yet optimal, individualized treatment of CF will require identification and targeting of disease modifiers. Here we use genome-wide association analysis to identify genetic modifiers of CF lung disease, the primary cause of mortality. Meta-analysis of 6,365 CF patients identifies five loci that display significant association with variation in lung disease. Regions on chr3q29 (MUC4/MUC20; P=3.3 × 10(-11)), chr5p15.3 (SLC9A3; P=6.8 × 10(-12)), chr6p21.3 (HLA Class II; P=1.2 × 10(-8)) and chrXq22-q23 (AGTR2/SLC6A14; P=1.8 × 10(-9)) contain genes of high biological relevance to CF pathophysiology. The fifth locus, on chr11p12-p13 (EHF/APIP; P=1.9 × 10(-10)), was previously shown to be associated with lung disease. These results provide new insights into potential targets for modulating lung disease severity in CF.
Referência(s)